期刊文献+

KDR siRNA表达载体的构建和鉴定 被引量:2

Construction and identification of siRNA expression vector targeting KDR
暂未订购
导出
摘要 目的构建针对血管内皮生长因子受体Ⅱ(VEGFR2),又称激酶功能区受体(KDR)的pSilencerTM3.1siRNA(smallinterferingRNA)表达载体,并在前列腺癌细胞PC3中观察其干扰效果.方法设计针对KDR基因编码区的寡核苷酸链,体外退火后克隆入经BamHⅠ,HindⅢ双酶切线性化的干扰载体pSilencerTM3.1-H1neo中,对重组质粒进行酶切分析和DNA系列测定.以脂质体法将pSilencerTM3.1-H1neo空载体和3个(pSilencer3.1-KDR1,pSilencer3.1-KDR2和pSilencer3.1-KDR3)重组质粒分别导人PC3前列腺癌细胞系.72h后用RT-PCR和Westernblotting技术检测各实验组前列腺癌细胞内KDRmRNA及蛋白水平的表达情况.结果经酶切鉴定及DNA测序,重组质粒中已插入了目的基因片断.转染KDR-siRNA的前列腺癌细胞,72h后,而以pSilencer3.1-KDR3的抑制KDRmRNA及蛋白表达效果最为有效,其抑制率约为55%.结论成功构建了针对KDR的RNA干扰表达载体pSilencer3.1-KDR1,pSilencer3.1-KDR2和pSilencer3.1-KDR3,pSilencer3.1-KDR3能有效抑制KDR在前列腺癌细胞中表达,为将其进一步应用于前列腺癌的治疗研究奠定了基础. AIM: To construct pSilencer^TM 3. 1-H1 small inferfefing RNA (siRNA) expression vector targeting human KDR gene and to observe its silencing effect in the PC3 prostate cancer cell line. METHODS: The designed oligos targeting KDR were cloned into the pSilencer^TM3.1-H1 neo vector, which was lineated after Bam HⅠ and Hind Ⅲ digestion. The recombimant vectors were confirmed by enzyme digestion analysis and DNA sequencing. The reeombimant vectors of pSilencer 3.1-KDR1, pSilencer 3.1-KDR2 and pSilencer 3. 1-KDR3 were transfected by liposome-mediated tranafection into the PC3 prostate cancer cell line with high metastasis potential. At 72 h after transfection, the expression of KDR at the levels of mRNA and protein was detected by RT-PCR and Western blotting. RESULTS: The pSilencerTM 3.1-H1 siRNA expression vectors were constructed and confirmed after the enzyme digestion analysis and the DNA sequencing. The siRNA expression vectors of pSilencer 3.1-KDR1, pSilencer 3.1- KDR2 and pSilencer 3. 1-KDR3, were successfully constructed. pSllencer 3.1-KDR3 was most effective in the 3 which down-regulated 55% mRNA and protein of KDR at 72 h after transfection. CONCLUSION: pSilencer^TM 3. 1-H1 siRNA expression vectors targeting KDR were successfully constructed. The expression of KDR gene was inhibited effectively in PC3 cells transfacted by pSilencer 3.1-KDR3 ,which laid a basis for its application in the treatment of prostate cancer.
出处 《第四军医大学学报》 北大核心 2006年第10期898-901,共4页 Journal of the Fourth Military Medical University
基金 国家863计划资助项目(2001AA215321)
关键词 血管内皮生长因子受体2 RNA 小分子干扰 PC3细胞系 vascular endothelial growth factor receptor-2 RNA, small interfering PC3 cell line
  • 相关文献

参考文献8

  • 1Strohmeyer D,Rossing C,Bauerfeind A,et al.Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer [J].Prostate,2000,45:216-224.
  • 2Ferrer FA,Miller LJ,Andrawis RI,et al.Angiogenesis and prostate cancer:In vivo andivitro expression of angiogenesis factors by prostate cancer cells [J].Urology,1998,51:161-167.
  • 3Ui-Tei K,Naito Y,Takahashi F,et al.Guidelines for the selection of highly effectivesiRNA sequences for mammalian and chick RNA interference [J].Nucleic Acids Res,2004,32(3):936-948.
  • 4Suhardja A,Hoffman H.Role of growth factors and their receptors in proliferation ofmicrovascular endothelial cells [J].Microsc Res Tech,2003,60:70-75.
  • 5Underiner TL,Ruggeri B,Gingrich DE,et al.Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti2 angiogenic agents in cancer therapy [J].Curr Med Chem,2004,11:731-745.
  • 6Witte L,Hicklin DJ,Zhu Z,et al.Monoclonal antibodies targeting the VEGF receptor-2 (Fl-k1/ KDR) as an anti-angiogenic therapeutic strategy [J].Cancer Metastasis Rev,1998,17(2):155-159.
  • 7Bruns CJ,Liu W,Davis DW,et al.Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases [J].Cancer,2000,89(3):488-499.
  • 8Sui G,Soohoo C,Affar el B,et al.A DNA vector-based RNAi technology to suppress gene expression in mammalian cells [J].Proc Natl Acad Sci USA,2002,99(8):5515-5520.

同被引文献10

  • 1周昌华,章崇杰.化学修饰小干扰RNA研究进展[J].国际检验医学杂志,2006,27(8):693-695. 被引量:2
  • 2刘久华,张炜.COX-2和VEGF在前列腺癌中的表达及其与肿瘤Gleason评分之间关系的研究[J].实用临床医药杂志,2007,11(1):53-56. 被引量:6
  • 3Song E,Zhu P, Lee SK,etal.Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors[J].Nat Biotechnol, 2005,23(6):709.
  • 4Dykxhoorn DM , Lieberman J. The silent revolution: RNA interference as basic biology, research tool, and therapeutic [J].Annu Rev Med, 2005, 56:401.
  • 5Louz D, Bergmans HE, Loos BP, et al. Cross-species transfer of viruses: implications for the use of viral vectors in biomedical research, gene therapy and as live-virus vaccines [J]. J Gene Med, 2005, 7(10): 1263.
  • 6Mittal V. Improving the efficiency of RNA interference in mammals [J]. Nat Rev Genet, 2004, 5(5): 355.
  • 7Bridge AJ, Pebernard S, Ducraux A, et al.Induction of an interferon response by RNAi vectors in mammalian cells [J]. Nat Genet, 2003, 34(3):263.
  • 8Zhu X, Green MR. Nonspecific,concentration--dependent stimulation and repression of mammalian gene expression by small interfering RNAs(siRNAs) [J]. RNA, 2004,10( 1):12.
  • 9Liao H,Wang JH. Biomembrane-permeable and Ribonuclease-resisrant siRNA with enhanced activity[J].Oligonucleotides,2005,15(3):196.
  • 10Elmen J,Thonberg H,Ljungberg K,et al.Locked nucleic acid(LNA) mediated improvements in siRNA stability and functionality[J].Nucleic Acids Res,2005,33(1):439.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部